Under the agreement, Ajinomoto will provide drug product aseptic fill-finish services for Humanigen at its San Diego, CA facility.

Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody. The drug neutralizes a key cytokine in the initiation of a cytokine storm, a known factor in COVID-19 complications.

As part of the randomized, placebo-controlled, double-blinded phase III study, the drug is being administered in multiple locations across the U.S.

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...

Abcore develops antibodies against COVID-19
Antibody research and development firm Abcore said that it's discovered and tested a panel of functional therapeutic candidates for the treatment of COVID-19.

SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...

Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.